Loading…
AgomAb Therapeutics NV is projected to decline to $12.50 by 2027, a -4% move from its current price of $13.08. AGMB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $12.32 | $13.08 | $13.89 | 0.00% |
| Jul 14 | $12.02 | $13.08 | $14.24 | 0.00% |
| Jul 15 | $11.79 | $13.08 | $14.52 | +0.01% |
| Jul 16 | $11.60 | $13.08 | $14.75 | +0.01% |
| Jul 17 | $11.44 | $13.08 | $14.96 | +0.01% |
| Jul 18 | $11.29 | $13.08 | $15.16 | +0.01% |
| Jul 19 | $11.16 | $13.08 | $15.34 | +0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.16 | $13.08 | $15.34 | +0.02% |
| Week 2 | $10.45 | $13.08 | $16.38 | +0.03% |
| Week 3 | $9.94 | $13.09 | $17.23 | +0.05% |
| Week 4 | $9.52 | $13.09 | $17.99 | +0.07% |
| Week 5 | $9.18 | $13.09 | $18.68 | +0.08% |
| Week 6 | $8.87 | $13.09 | $19.32 | +0.10% |
| Week 7 | $8.60 | $13.09 | $19.94 | +0.11% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company that develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States.
Its product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models.
The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
AgomAb Therapeutics NV trades at $13.52 per share with a market capitalization of $665.83M and ranks 2811. The near-term technical picture shows bullish sentiment with RSI(14) at 60, and a 50-day simple moving average of $11.48. A support level sits at $9.61 and a resistance at $17.82, with a 30-day price range from $8.65 to $21.12.
Annualized volatility stands at 100%. The long-run forecast envisions upside across multiple years, with 2030 averaging $18.94 and a max of $38.35 (ROI 40.1) and 2050 averaging $72.39 with a max of $166.50 (ROI 435.4).
A major floor 59.5% below — a decisive break under it would weaken the trend.
The nearest floor, 26.5% below — buyers have tended to step in here.
The nearest ceiling, 36.2% above — a clean break opens room to run.
A major ceiling 66.0% above — clearing it would confirm fresh momentum.
Key AGMB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AGMB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.13 | Sell | $13.07 | Buy |
| MA 10 | $13.48 | Sell | $12.99 | Buy |
| MA 20 | $12.26 | Buy | $12.56 | Buy |
| MA 50 | $11.65 | Buy | $12.04 | Buy |
| MA 100 | $12.19 | Buy | $12.31 | Buy |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.58 | Neutral |
| Stoch RSI (14) | 11.74 | Buy |
| CCI (20) | 38.57 | Neutral |
| Williams %R (14) | -79.26 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 9.55 | Buy |
| Bollinger %B (20,2) | 0.61 | Neutral |
| Stochastic %K (14) | 20.74 | Neutral |
| TRIX (15) | 0.71 | Buy |
| Awesome (5,34) | 1.35 | Buy |
| Ultimate (7,14,28) | 53.26 | Neutral |
| Momentum (10) | -0.35 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 12.92 | Buy |
| ADX (14) | 14.61 | Neutral |
| ATR (14) | 0.81 | Info |
The 30-day picture shows bullish conditions with RSI(14) at 60 and a price that has traded within a $8.65 to $21.12 range. The 50-day moving average sits at $11.48, providing a nearby trend line above the current price. Investors may watch the $9.61 support and $17.82 resistance as near-term benchmarks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.61 | $13.08 | $17.78 | 0% | Neutral | |
| $8.17 | $12.50 | $20.69 | -4% | Neutral | |
| $7.66 | $13.00 | $23.43 | -1% | Neutral | |
| $7.58 | $14.12 | $27.11 | +8% | Neutral | |
| $8.46 | $17.19 | $34.77 | +31% | Bullish | |
| $10.50 | $23.21 | $49.08 | +77% | Bullish | |
| $11.14 | $24.75 | $54.41 | +89% | Bullish | |
| $10.99 | $24.42 | $55.57 | +87% | Bullish | |
| $10.98 | $24.40 | $56.13 | +87% | Bullish | |
| $9.73 | $21.63 | $49.75 | +65% | Bullish | |
| $19.55 | $43.45 | $99.93 | +232% | Bullish | |
| $28.18 | $62.62 | $144.03 | +379% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.61 | $13.08 | $16.47 | +0.00% |
| August 2026 | $10.23 | $12.74 | $16.71 | -2.63% |
| September 2026 | $10.30 | $13.11 | $17.72 | +2.92% |
| October 2026 | $10.43 | $13.52 | $18.74 | +3.15% |
| November 2026 | $9.74 | $12.84 | $18.15 | -5.06% |
| December 2026 | $9.22 | $12.34 | $17.78 | -3.82% |
Click any year to see its month-by-month AGMB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, AGMB could reach as high as $17.78, with a base case around $13.08 and support toward $9.61 — roughly 0% from $13.08. Price action looks broadly range-bound.
Expect AGMB to range from $8.17 to $20.69 through 2027. The $12.50 average target implies a -4% move from current prices. That is -4% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The AGMB price prediction for 2028 points to an average of $13.00 (low $7.66, high $23.43) — a potential decline of -1% on today's $13.08. Price action looks broadly range-bound.
In 2029, AGMB is projected to trade between $7.58 and $27.11, averaging $14.12 — a potential gain of +8% from today's $13.08. That is up +9% on the projected 2028 average. A consolidation phase looks the most probable path here.
AgomAb Therapeutics NV's 2030 outlook centres on $17.19, within a $8.46 to $34.77 range. That is up +22% on the projected 2029 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2031, AGMB could reach as high as $49.08, with a base case around $23.21 and support toward $10.50 — roughly +77% from $13.08. Buyers look set to stay in control over this stretch.
Expect AGMB to range from $11.14 to $54.41 through 2032. The $24.75 average target implies a +89% move from current prices. That is up +7% on the projected 2031 average. Momentum favours further upside here.
The AGMB price prediction for 2033 points to an average of $24.42 (low $10.99, high $55.57) — a potential gain of +87% on today's $13.08. Buyers look set to stay in control over this stretch.
In 2034, AGMB is projected to trade between $10.98 and $56.13, averaging $24.40 — a potential gain of +87% from today's $13.08. That is 0% versus the projected 2033 average. Momentum favours further upside here.
AgomAb Therapeutics NV's 2035 outlook centres on $21.63, within a $9.73 to $49.75 range. That is -11% versus the projected 2034 average. That marks a +65% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, AGMB could reach as high as $99.93, with a base case around $43.45 and support toward $19.55 — roughly +232% from $13.08. Momentum favours further upside here.
Expect AGMB to range from $28.18 to $144.03 through 2050. The $62.62 average target implies a +379% move from current prices. That is up +44% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AGMB today (≈ 76.452599 AGMB) could be worth
$4,787.66
+$3,787.66 (+379%) by 2050 · US Dollar
Based on the average projected AGMB price of $62.62 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AGMBwould be worth at today's price.
$1,000 invested in AGMB on Feb 6, 2026 (≈ 68.259387 AGMB) would be worth
$892.83
-$107.17 (-10.7%) today · 0.89× · US Dollar
Based on a AGMB entry price of $14.65 vs. today's $13.08.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.65 | $1,033.99 | +3.4% |
| 1 month ago | $10.33 | $1,266.21 | +26.6% |
| 3 months ago | $10.54 | $1,240.99 | +24.1% |
| All time ago | $14.65 | $892.83 | -10.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AGMB forecast.
Our base-case forecast reaches $26.00 around 2040.
Implied market cap at $26.00: $1.28B
The multi-year forecast points to meaningful upside, with a 2030 average price of $18.94 and a max $38.35, yielding a 40.1% ROI and a bullish sentiment. The 2040 forecast shows an average of $48.28 with a max of $111.05 and a 257.1% ROI, continuing the bullish outlook. By 2050, the average is projected to $72.39 with a max of $166.50 and a 435.4% ROI, underscoring substantial long-term upside, albeit with uncertainty and the usual investment risks.
Tap a question to reveal the answer.
2030: min $9.32, avg $18.94, max $38.35; ROI 40.1; sentiment BULLISH.
Forecasts show bullish sentiment from 2030 onward with an average price of $18.94 in 2030 and higher through 2050, though some years such as 2027 show a negative or flat ROI (e.g., ROI -2 in 2027; ROI 0 in 2026) and overall outcomes are not guaranteed.
Yes. The 2040 max is $111.05 and the 2050 max is $166.50, indicating the potential to exceed $100 in the forecast horizon.
$8.65 to $21.12.
Current price is $13.52 and market cap is $665.83M.
AgomAb Therapeutics NV Community Discussion
0Share your AgomAb Therapeutics NV price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.